AU3036297A - Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin - Google Patents
Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutininInfo
- Publication number
- AU3036297A AU3036297A AU30362/97A AU3036297A AU3036297A AU 3036297 A AU3036297 A AU 3036297A AU 30362/97 A AU30362/97 A AU 30362/97A AU 3036297 A AU3036297 A AU 3036297A AU 3036297 A AU3036297 A AU 3036297A
- Authority
- AU
- Australia
- Prior art keywords
- features
- mycobacteria
- adhesion
- heparin
- host cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 229960002897 heparin Drugs 0.000 title abstract 2
- 229920000669 heparin Polymers 0.000 title abstract 2
- 238000010367 cloning Methods 0.000 title 1
- 230000025845 adhesion to host Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 abstract 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000000405 serological effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention features peptide sequences enabling mycobacteria adhesion to host cells, in particular to epithelial cells. More particularly, the invention features a mycobacterial antigen of the heparin-binding haemagglutinin type (HBHA) obtained from Mycobacterium bovis BCG or Mycobacterium tuberculosis. The invention also features a recombinant peptide sequence enabling mycobacteria adhesion to host cells. The invention particularly features the expression product of an Escherichia coli strain transformed with a nucleotide sequence coding for a protein enabling mycobacteria adhesion to host cells. These peptide sequences can be used in immunogenic compositions, for preparing vaccines against mycobacterial infections, and for mycobacterial infection serological diagnosis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9606168A FR2748748B1 (en) | 1996-05-17 | 1996-05-17 | IDENTIFICATION AND CLONING OF A MYCOBACTERIAL ANTIGEN CORRESPONDING TO A HEPARIN BINDING HEMAGGLUTIN |
| FR9606168 | 1996-05-17 | ||
| PCT/FR1997/000886 WO1997044463A2 (en) | 1996-05-17 | 1997-05-20 | Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3036297A true AU3036297A (en) | 1997-12-09 |
Family
ID=9492234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU30362/97A Abandoned AU3036297A (en) | 1996-05-17 | 1997-05-20 | Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0914437B1 (en) |
| AT (1) | ATE328085T1 (en) |
| AU (1) | AU3036297A (en) |
| DE (1) | DE69736000T2 (en) |
| DK (1) | DK0914437T3 (en) |
| ES (1) | ES2267142T3 (en) |
| FR (1) | FR2748748B1 (en) |
| PT (1) | PT914437E (en) |
| WO (1) | WO1997044463A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2793492A1 (en) * | 1999-05-11 | 2000-11-17 | Pasteur Institut | NEW AFFINITY PURIFICATION PROCESS |
| US6316205B1 (en) | 2000-01-28 | 2001-11-13 | Genelabs Diagnostics Pte Ltd. | Assay devices and methods of analyte detection |
| FR2832410B1 (en) | 2001-11-19 | 2004-04-02 | Pasteur Institut | RECOMBINANT MYCOBACTERIAL ANTIGEN OF HEMAGGLUTININ TYPE OF METHYLATED HEPARIN BINDING, METHODS OF PREPARATION AND IMMUNOGENIC COMPOSITIONS COMPRISING SUCH ANTIGEN |
| EP1573038A2 (en) * | 2002-07-19 | 2005-09-14 | Arizona Board Of Regents | A high resolution typing system for pathogenic mycobacterium tuberculosum |
| FR2872579B1 (en) * | 2004-06-30 | 2006-11-24 | Pasteur Institut | DETECTION OF TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS INFECTION USING HBHA |
| US8475735B2 (en) | 2004-11-01 | 2013-07-02 | Uma Mahesh Babu | Disposable immunodiagnostic test system |
| US20130018178A1 (en) | 2009-06-22 | 2013-01-17 | Px Therapeutics | Method for the purification of hbha |
| WO2012038486A1 (en) | 2010-09-21 | 2012-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method for obtaining a purified hbha polypeptide or fragment thereof |
| WO2012177520A2 (en) * | 2011-06-20 | 2012-12-27 | Matthias Rath | Oligopeptides and their use for treating infectious diseases |
| GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
| CA3045952A1 (en) | 2016-12-07 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Novel process |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| JP7291633B2 (en) | 2017-05-30 | 2023-06-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Method for manufacturing an adjuvant |
| CA3083078A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
| US20220235095A1 (en) | 2019-06-05 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Saponin purification |
-
1996
- 1996-05-17 FR FR9606168A patent/FR2748748B1/en not_active Expired - Fee Related
-
1997
- 1997-05-20 EP EP97925109A patent/EP0914437B1/en not_active Expired - Lifetime
- 1997-05-20 DK DK97925109T patent/DK0914437T3/en active
- 1997-05-20 PT PT97925109T patent/PT914437E/en unknown
- 1997-05-20 AU AU30362/97A patent/AU3036297A/en not_active Abandoned
- 1997-05-20 DE DE69736000T patent/DE69736000T2/en not_active Expired - Lifetime
- 1997-05-20 WO PCT/FR1997/000886 patent/WO1997044463A2/en active IP Right Grant
- 1997-05-20 AT AT97925109T patent/ATE328085T1/en active
- 1997-05-20 ES ES97925109T patent/ES2267142T3/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997044463A2 (en) | 1997-11-27 |
| FR2748748B1 (en) | 1998-11-06 |
| ES2267142T3 (en) | 2007-03-01 |
| DE69736000D1 (en) | 2006-07-06 |
| WO1997044463A3 (en) | 1998-01-29 |
| DE69736000T2 (en) | 2007-01-25 |
| EP0914437B1 (en) | 2006-05-31 |
| PT914437E (en) | 2006-10-31 |
| EP0914437A2 (en) | 1999-05-12 |
| ATE328085T1 (en) | 2006-06-15 |
| FR2748748A1 (en) | 1997-11-21 |
| DK0914437T3 (en) | 2006-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3036297A (en) | Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin | |
| BR9906927A (en) | Neisseria meningitidis proteins | |
| CY1106350T1 (en) | TUBERCULOSIS VACCINE | |
| BR9408135A (en) | Abundant extra-cellular products and processes for their production and use | |
| WO1999024578A3 (en) | Neisserial antigens | |
| NZ507378A (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| MY119003A (en) | Bacterial antigens and vaccine compositions | |
| WO1990000594A3 (en) | Recombinant mycobacterial expression vehicles and uses therefor | |
| EP1092774A3 (en) | Borrelia burgdorferi antigen OspA, gene encoding it and uses thereof | |
| AU3431497A (en) | DNA immunization against Chlaymdia infection | |
| Meehan et al. | Affinity purification and characterization of a fibrinogen-binding protein complex which protects mice against lethal challenge with Streptococcus equi subsp. equi | |
| WO2000011214B1 (en) | Molecular differences between species of the m. tuberculosis complex | |
| CA2523084A1 (en) | Tuberculosis vaccine with improved efficacy | |
| AU2529095A (en) | Vaccine against mycobacterial infections | |
| Rao et al. | Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette–Guerin | |
| Khademi et al. | Mycobacterium tuberculosis HspX/EsxS fusion protein: gene cloning, protein expression, and purification in Escherichia coli | |
| CA2372583A1 (en) | Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines | |
| BR0309491A (en) | Vaccine composition, immunogenic composition, use of an e7 protein and neutralizing antibodies | |
| IL156041A0 (en) | Nucleic acid adjuvants | |
| AU6029898A (en) | Abundant extracellular products and methods for their production and use | |
| Amara et al. | Differential immunogenicity of novel Mycobacterium tuberculosis antigens derived from live and dead bacilli | |
| Tsuji et al. | Charge heterogeneity of heat-labile enterotoxins from human enterotoxigenic Escherichia coli | |
| WO2004056316A8 (en) | Vaccines against hiv-1 tat protein to generate neutralizing antibodies | |
| NZ512308A (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof | |
| AU6821300A (en) | Attenuated mutant enteropathogenic e. coli (epec) strains, process for their production and their use |